SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
Protox Therapeutics (PRX.TO): A Molecular Approach to Surgery
AEZS
|
|
|
-12.10%
in
36 days
<font> Protox Therapeutics </font> (TSX: PRX.TO) applies genetic engineering techniques to create innovative, targeted protein-based therapeutics which are focused on prostate conditions and cancer. The Company’s clinical-stage pipeline is based on the PORxin and INxin technology platforms. Lead drugs in clinical development include PRX302 for the treatment of benign prostatic hyperplasia (BPH or enlarged prostate) and localized prostate cancer as well as PRX321 for primary brain cancer (glioblastoma multiforme / GBM and astrocytoma). <> <> <font> <>http://www.mik...
|
New Indexes to Track Healthcare Trends and More
AEZS
|
|
|
-51.56%
in
63 days
(closed on 10/06/09)
Below are links and descriptions for 23 new stock indexes I have created, revised, and tracked over the past few years which are now featured at a new website called Investars YOU. The new site includes automated index tracking, allows investors to create custom stock portfolios based on their individual preferences, and now features free access to all of the component stocks in each of my indexes. Some of the top performing stocks from my healthcare indexes on a year-to-date basis are highlighted below.
Cosmetic & Restorative Medicine Index: Allergan (NYSE:AGN) (+38%) <> The <> ...
|
Key Developments for AEZA
AEZS
|
|
|
-37.71%
in
134 days
AEterna Zentaris Inc. Announces New Data Published On Its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports Its Use In Alcohol Addiction
Tuesday, 7 Jul 2009 07:15am EDT AEterna Zentaris Inc. announced publication in the American scientific journal, Proceedings of the National Academy of Sciences, of new data supporting the use of AEterna Zentaris' ghrelin receptor antagonist compound, AEZS-123 (JMV2959), for the treatment of alcohol dependence that involves ghrelin. Ghrelin is a hormone produced by the stomach and acting in the brain. Compelling evidence obtained with...
|
FDA Calendar Extreme Trades: 30 Stocks Under $5
AEZS
|
|
|
-2.29%
in
3 days
(closed on 08/04/09)
<> Below are extreme trades among 30 companies with stock prices under $5 from the BioMedReports.com FDA Calendar, which includes 292 entries as of 8/1/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-stage c...
|
From the Blogosphere
Trading Radar for 11/11: Macy's (M), Progressive (PGR), Advanced Auto Parts (AAP), Computer Sciences (CSC) Report
|
The Trading Radar highlights key earnings and economic announcements for tomorrow's trading session:<u>Before Market Opens:</u>Earnings:Aeterna Zentaris Inc. (NASDAQ: AEZS) – consensus loss $0.21Aracruz Cellulose S (NASDAQ: AARA) – consensus loss $0.61Atrinsic, Inc. (NASDAQ: ATRN) – no consensus Baldwin Technology (NYSE: BLD) – consensus EPS $0.26China Housing & Land Development Inc. (NASDAQ: CHLN) – consensus EPS $0.08Crown Crafts (NASDAQ: CRWS) – no consensusFlowers Foods (NYSE: FLO) – consensus EPS $0.34Global Options (NASDAQ: GLOI) – consensus EPS $0.00Grubb & Ellis (NYSE: GBE) – no con...
|
AEterna Zentaris: Expecting Good News?
AEterna Zentaris (AEZS) is a speculative biopharmaceutical company that demonstrates why it is always best to choose speculative biotech / pharma plays that have multiple drug candidates in the pipeline and are not 'one trick ponies.'
When the company announced that its lung cancer drug, Perifosine, failed to prove effective in a mid-stage trial, the stock plummeted to under thirty cents. However, because the company had more to offer than just Perifosine, the stock quickly recovered and closed the week at $2.62.
|
Analyst upgrades, downgrades and initiations: AKAM, MRVL, THRX, DELL, CRNT, TRV, AEIS ...
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on AEZS |
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About AETERNA ZENTARIS
- Answers.com
